Navigation Links
Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
Date:2/9/2009

Adjusted Results Excluding Special Items * ------------------ Operating Income $123.3 $114.2 8.0% $363.7 $327.1 11.2% Diluted Earnings per Share $1.29 $1.08 19.4% $3.63 $3.25 11.7% * See "Non-GAAP Financial Measures," where the impacts of certain items on reported results are discussed.

Fourth Quarter Discussion

Recurring revenue comprised of supplies, test kits, service and operating-type lease payments, was $610 million or approximately 75% of total revenue. Recurring revenue continued its steady performance increasing 5.1%, or 8.9% in constant currency. In Clinical Diagnostics, recurring revenue increased 5.7%, or 9.6% in constant currency, led by Access Immunoassay constant currency growth of more than 20%.

Total cash instrument sales were flat with prior year quarter in constant currency, reflecting strong prior year sales and a decline in Life Sciences of 10.4%, or 6.3% in constant currency.

On a geographic basis, fourth quarter revenue in the United States increased 7.4%. In constant currency, International revenue grew 5.8%, with 9.7% growth in Clinical Diagnostics, offset partially by a 6% decline in Life Sciences.

Scott Garrett, chairman, president and chief executive officer, said, "Fourth quarter results demonstrate the ongoing strength of our Clinical Diagnostics business worldwide and the stability of sector fundamentals. Continued robust growth of recurring revenue at stable margins in combination with disciplined expense management allowed us to deliver on our earnings commitments, despite flat cash instrument sales."

Gross profit grew 4.4% to $385.7 million, as gross margin increased 70 basis points to 47.5% versus fourth quarter 2007. Operating income was $115.1 million. On an adjusted basis, operating income increased 8% to $123.3 million
'/>"/>

SOURCE Beckman Coulter - IR
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... In the same week that state senators in Wisconsin ... to include ethanol, policymakers in another Midwestern state were ... , ,Agri-business giant Louis Dreyfus Corp. announced it ... northern Indiana, where it plans to crush nearly 50 ...
... company in central Wisconsin has announced its plans ... offerings of high-speed Internet and voice over IP services. ... serves about 28,000 customers. CEO Douglas Wenzlaff told reporters ... Madison and Eau Claire. Its existing base is in ...
Cached Biology Technology:Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 2Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 3
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... in those green coffee bean dietary supplements often touted ... obese laboratory mice fed a high-fat diet when given at ... in ACS, Journal of Agricultural and Food Chemistry . ... fat in the liver. Vance Matthews, Kevin Croft ...
... 2013: A new study presented today at EULAR 2013, ... shows that one in eight patients at risk of ... over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat ... NSAID users, over one-third had taken the medication for ...
... show ways in which we can markedly improve drug targeting ... imaging techniques. In real time and in three dimensions, ... active cancer cells respond to a particular drug. They can ... to administer drugs. Finally, using preclinical models of the disease, ...
Cached Biology News:Patients use OTC NSAIDs even when they have a high risk of serious side effects 2Nanotechnology helps track and improve drug action in pancreatic cancer 2
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... Imaging's proprietary Focus™ detector technology, while precisily ... R4. The microPET Focus 120 offers ... PET scanner. Focus scanners also possess ... based PETsystems. The combination of high ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
Biology Products: